Evaluation of a New Cardiac Biomarker Assay

PHASE3CompletedINTERVENTIONAL
Enrollment

1,101

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2014

Conditions
Acute Coronary SyndromeAcute Myocardial Infarction
Interventions
DEVICE

ARCHITECT STAT High Sensitive Troponin I Assay

"Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.~Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit."

Trial Locations (12)

11777

John T Mather Memorial Hospital, Port Jefferson

17033

Pennsylvania State University- Hershey Medical Center, Hershey

27710

Duke University Medical Center, Durham

33309

Nationwide Laboratory Services, Fort Lauderdale

44195

Cleveland Clinic Foundation, Cleveland

77802

Hospital Physicians in Clinical Research, Bryan

78752

Hospital Physicians in Clinical Research, Austin

85224

Chandler Regional Medical Center, Chandler

94304

Stanford University School of Emergency Medicine, Palo Alto

98225

St Joseph Hospital, Bellingham

19104-4283

Hospital of the University of Pennsylvania, Philadelphia

22908-2877

Dept of Emergency Medicine University of Virginia, Charlottesville

All Listed Sponsors
lead

Abbott Diagnostics Division

INDUSTRY

NCT01608100 - Evaluation of a New Cardiac Biomarker Assay | Biotech Hunter | Biotech Hunter